Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 12, 2014, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $463.50 to $302,316,738.76.

Highlighted Stocks Traded by Insiders:

EnerSys (ENS) - FREE Research Report

Craig John D, who is Chairman, President & CEO at EnerSys, sold 892 shares at $70.00 on May 12, 2014. Following this transaction, the Chairman, President & CEO owned 281,985 shares meaning that the stake was reduced by 0.32% with the 892-share transaction.

The shares most recently traded at $69.58, down $0.42, or 0.6% since the insider transaction. Historical insider transactions for EnerSys go as follows:

  • 4-Week # shares sold: 3,216
  • 12-Week # shares sold: 133,168
  • 24-Week # shares sold: 133,168

The average volume for EnerSys has been 360,900 shares per day over the past 30 days. EnerSys has a market cap of $3.2 billion and is part of the industrial goods sector and industrial industry. Shares are down 0.34% year-to-date as of the close of trading on Monday.

EnerSys manufactures, markets, and distributes industrial batteries in the Americas, Europe, the Middle East, Africa, and Asia. The stock currently has a dividend yield of 1.03%. The company has a P/E ratio of 17.1. Currently, there are 3 analysts who rate EnerSys a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENS - FREE

TheStreet Quant Ratings rates EnerSys as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full EnerSys Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Hornbeck Offshore Services (HOS) - FREE Research Report

Melcher Patricia B, who is Director at Hornbeck Offshore Services, bought 3,000 shares at $39.54 on May 12, 2014. Following this transaction, the Director owned 43,645 shares meaning that the stake was reduced by 7.38% with the 3,000-share transaction.

The shares most recently traded at $41.84, up $2.30, or 5.49% since the insider transaction. Historical insider transactions for Hornbeck Offshore Services go as follows:

  • 4-Week # shares bought: 25,500
  • 12-Week # shares bought: 25,500
  • 12-Week # shares sold: 337
  • 24-Week # shares bought: 25,500
  • 24-Week # shares sold: 337

The average volume for Hornbeck Offshore Services has been 617,300 shares per day over the past 30 days. Hornbeck Offshore Services has a market cap of $1.5 billion and is part of the basic materials sector and energy industry. Shares are down 15.9% year-to-date as of the close of trading on Monday.

Hornbeck Offshore Services, Inc., through its subsidiaries, operates offshore supply vessels (OSVs) and multi-purpose support vessels (MPSVs) primarily in the U.S. Gulf of Mexico and Latin America. The company has a P/E ratio of 20.5. Currently, there are 7 analysts who rate Hornbeck Offshore Services a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on HOS - FREE

TheStreet Quant Ratings rates Hornbeck Offshore Services as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Hornbeck Offshore Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Pacira Pharmaceuticals (PCRX) - FREE Research Report

Wicki Andreas, who is Director at Pacira Pharmaceuticals, sold 23,220 shares at $75.76 on May 12, 2014. Following this transaction, the Director owned 1.6 million shares meaning that the stake was reduced by 1.43% with the 23,220-share transaction.

The shares most recently traded at $76.31, up $0.55, or 0.72% since the insider transaction. Historical insider transactions for Pacira Pharmaceuticals go as follows:

  • 12-Week # shares bought: 1,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 22,746

The average volume for Pacira Pharmaceuticals has been 544,300 shares per day over the past 30 days. Pacira Pharmaceuticals has a market cap of $2.6 billion and is part of the health care sector and drugs industry. Shares are up 34.48% year-to-date as of the close of trading on Monday.

Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, commercializes, and manufactures pharmaceutical products primarily for use in hospitals and ambulatory surgery centers worldwide. Currently, there are 7 analysts who rate Pacira Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PCRX - FREE

TheStreet Quant Ratings rates Pacira Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and disappointing return on equity. Get the full Pacira Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null